InvestorsHub Logo


Followers 42
Posts 2176
Boards Moderated 0
Alias Born 07/17/2014


Re: None

Tuesday, 05/17/2022 8:44:25 AM

Tuesday, May 17, 2022 8:44:25 AM

Post# of 1569
AdCom later this year. PDUFA maintained Nov. 30, 2022

[CYTK] was informed that the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil. Cytokinetics expects the FDA to inform it of the date and topics for the Advisory Committee Meeting in a subsequent communication. A late-cycle communication meeting has been proposed to occur later this year.

Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).

The FDA has assigned the NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2022.

Best of luck with your investments!
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News